Treatment of Patients With Pancreatic Endocrine Tumours Using a New Long-Acting Somatostatin Analogue Symptomatic and Peptide Responses.

Gut - United Kingdom
doi 10.1136/gut.26.5.438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Somatostatin Analogue Treatment of Neuroendocrine Tumours.

Postgraduate Medical Journal
Medicine
1996English

Successful Treatment With a Long-Acting Somatostatin Analogue(SMS201-995) in a Patient With Malignant Carcinoid Syndrome.

Japanese Journal of Medicine
1988English

Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in Somatostatin Analogue-Naive Patients With Acromegaly

Journal of Endocrinological Investigation
EndocrinologyMetabolismDiabetes
2009English

Glucose Tolerance During Long Term Treatment With a Somatostatin Analogue

BMJ
1987English

Somatostatin Analogue Scintigraphy in Carcinoid Tumours

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
1993English

Long Term Treatment by a Long Acting Somatostatin Analogue (Sms 201–995) in a 4 Months Boy Presenting With Primary Permanent Hyperinsulinism

Pediatric Research
Child HealthPediatricsPerinatology
1988English

Pharmacokinetic and Pharmacodynamic Properties of a Long-Acting Formulation of the New Somatostatin Analogue, Lanreotide, in Normal Healthy Volunteers.

British Journal of Clinical Pharmacology
Pharmacology
1994English

A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours

International Journal of Surgical Oncology
SurgeryOncology
2015English

The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children With Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia

Hormone Research in Paediatrics
Child HealthEndocrinologyPerinatologyPediatricsMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy